Skip to main content


Swipe om te navigeren naar een ander artikel

05-10-2017 | Letter to the Editor | Uitgave 11/2017 Open Access

Netherlands Heart Journal 11/2017

Very-long-term efficacy of bioresorbable vascular scaffolds

Netherlands Heart Journal > Uitgave 11/2017
R. Shah
To the Editor,
I read with great interest Elias and colleagues’ recent meta-analysis in which 2‑year follow-up data were used for all trials with the exception of ABSORB II [ 1]. However, sensitivity analysis using 2‑year follow-up data from ABSORB II does not change their summary result for target lesion failure (TLF) (RR 1.31; 95% CI 1.08–1.58; p = 0.004). Thus, based on this meta-analysis, we can conclude that bioresorbable vascular scaffolds (BVSs) are associated with worse safety and efficacy outcomes up to 2 years after implantation; however, it is not clear if this is true beyond 2 years.
Since the publication of this work, two randomised controlled trials (RCTs) in addition to ABSORB II have reported 3‑year results [ 2, 3]. In ABSORB-Japan, only one scaffold thrombosis occurred (0.4%) in the BVS group between years 2 and 3 [ 3]. The TLF rate was exactly the same (1.6%) for both the BVS and metallic stent groups. In ABSORB-China, no stent thromboses occurred in either group between years 2 and 3 [ 2]. A landmark meta-analysis (using TLF between years 2 and 3) of these three trials suggests no statistically significant difference in TLF between the BVS and metallic stent groups (RR 1.78; 95% CI 0.68–4.62; p = 0.237).
These new findings suggest that efficacy problems with BVSs might recede 2 years post-implantation. While these findings are encouraging, they are not confirmatory; to be so, continued long-term follow-up of all relevant RCTs is needed.
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Onze productaanbevelingen

Netherlands Heart Journal

Het Netherlands Heart Journal wordt uitgegeven in samenwerking met de Nederlandse Vereniging voor Cardiologie en de Nederlandse Hartstichting. Het tijdschrift is Engelstalig en wordt gratis beschikbaa ...

Over dit artikel

Andere artikelen Uitgave 11/2017

Netherlands Heart Journal 11/2017 Naar de uitgave

Editor’s Comment

Resuscitation on the pitch